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In 2007 the European Society of Hypertension, the American Heart Association 
and the International Society of Hypertension-World Health Organization published 
new guidelines for the management of hypertension. The need of developing new 
guidelines for hypertension is due to recently published research data suggesting 
important modifications in the diagnostic and therapeutic strategies in clinical prac-
tice. The implementation of the new guidelines is expected to achieve more effective 
cardiovascular protection in hypertensive patients.  
t O t A L  c A r D I O v A s c U L A r  r I s K  A s s E s s m E N t  
I N  D E c I s I O N  m A K I N G
The European as well as the American guidelines of 2007 in general proposed 
more aggressive approaches compared to previous guidelines, regarding treatment 
initiation and also blood pressure goals. In both guidelines the intervention strategy 
is decided on the basis of total cardiovascular risk assessment. High risk hypertensive 
patients are regarded as those with (a) stage III hypertension, (b) asymptomatic target 
organ damage (left ventricular hypertrophy, microalbuminuria, atherosclerosis of 
carotid arteries), (c) diabetes mellitus, (d) at least three additional cardiovascular risk 
factors (e.g. metabolic syndrome), or (e) established cardiovascular disease (coronary 
heart disease, stroke or transient ischemic attack, renal insufficiency or proteinuria, 
intermittent claudication, aortic aneurysm).
t r E A t m E N t  I N I t I A t I O N 
According to the new guidelines, drug treatment is recommended in all subjects 
with consistent elevation of blood pressure above 140 mmHg systolic and/or 0 mmHg 
diastolic. In all subjects with high total cardiovascular risk, treatment initiation is 
indicated in lower blood pressure levels (systolic above 130 mmHg and/or diastolic 
above 85 mmHg). The higher the blood pressure level the shorter should be the du-
ration of observation before treatment initiation. In high risk hypertensives prompt 
drug treatment initiation is recommended, whereas in those at low risk a period of 
observation by applying non-pharmacological measures (lifestyle modification) for up 
1-12 months (according to the level of total risk) might be allowed.
b L O O D  P r E s s U r E  G O A L 
In hypertensive subjects with low total cardiovascular risk, the goal of treatment is 
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to reduce office blood pressure below 140 mmHg systolic and 
0 mmHg diastolic and even lower if treatment is well tolerated 
(as it is the case in most patients). In all high risk hypertensives 
the goal of treatment is lower (systolic below 130 mmHg and 
diastolic 80 mmHg). Reaching optimal blood pressure con-
trol is essential in order to achieve effective protection from 
cardiovascular events. Inadequate blood pressure control is 
associated with lesser cardiovascular protection.
f I r s t  L I N E  A N t I H Y P E r t E N s I v E 
D r U G s
The primary criterion for choosing antihypertensive drugs 
is their proven ability to prevent cardiovascular morbidity and 
mortality in large outcome trials. In the recent American, 
International and British hypertension guidelines four classes 
of drugs are recommended as first line treatment of hyper-
tension: thiazide diuretics, angiotensin converting enzyme 
inhibitors (ACEIs), angiotensin receptor blockers (ARBs) 
and calcium channel blockers (CCBs). 
Traditional cardiovascular drugs such as beta-blockers 
are no longer recommended as first line treatment in hyper-
tension, unless there is a specific indication (e.g. myocardial 
infarction or heart failure). The European guidelines made 
a more conservative statement for beta-blockers focusing on 
the negative metabolic effects of these drugs. According to the 
European guidelines beta-blockers remain a first line choice 
for the treatment of hypertension. However, these drugs, 
and particularly their combination with diuretics, should be 
avoided in hypertensive patients with metabolic syndrome or 
with high risk of developing diabetes mellitus, unless there is 
a specific indication for their use. 
c O m b I N A t I O N  A N t I H Y P E r t E N s I v E 
P H A r m A c O t H E r A P Y
Using antihypertensive drug monotherapy the recom-
mended blood pressure goals can be reached in fewer than 
50% of hypertensive patients. In most cases combination of 
2-3 and often more drugs is needed. This is particularly true 
in high risk hypertensives who have more difficult to control 
hypertension and also lower treatment target. 
In the new guidelines emphasis has been placed in the 
critical role of combination pharmacotherapy in order to 
achieve optimal blood pressure control. The rationale for 
combining drugs is to achieve larger reduction in blood 
pressure. The additional antihypertensive effect is larger for 
some drug combinations and weaker for others. Combina-
tion of drugs with different and complementary mechanisms 
of action provide strong synergistic blood pressure lowering 
effect (e.g. renin angiotensin system blockers combined with 
diuretics or CCBs). On the other hand, drugs sharing com-
mon mechanisms of action provide smaller additional blood 
pressure lowering effect (e.g. ACEIs combined with ARBs or 
beta-blockers). However, the primary criterion for choosing 
drug combinations should be their proven ability to provide 
long-term cardiovascular protection.
An additional benefit obtained by the appropriate selec-
tion of antihypertensive drug combinations is the potential to 
reduce the incidence of adverse effects of the drugs. In other 
words, the addition of a second drug might reduce the adverse 
effects of the first one, or the reverse. For example, ACEIs 
and ARBs reduced the incidence of hypokalemia induced 
by diuretics and also the ankle edema induced by CCBs. In 
addition, beta-blockers attenuate the tachycardia induced by 
dihydropiridine CCBs and diuretics attenuate the counteregu-
latory sodium retention induced by all vasodilatory drugs.
In most cases treatment initiation with monotherapy is 
indicated. According to the American and the European hy-
pertension guidelines treatment initiation with a combination 
of two drugs should be considered when there is a consistent 
rise in blood pressure of more than 20 mmHg systolic and/or 
10 mmHg diastolic above the recommended goal, particularly 
in subjects with high total cardiovascular risk.
The use of fixed dose combinations is a very popular ther-
apy in hypertension. Many fixed dose combinations of ACEIs 
or ARBs with thiazide diuretics (mostly hydrochlorothiazide) 
are available and widely used. Apart from the strong additive 
antihypertensive effect provided by these combinations, it 
should be remembered that the vast majority of the outcome 
trials that assessed the efficacy of ACEIs and ARBs in im-
proving prognosis have used these drugs in combination with 
thiazide diuretics. The combination of CCBs with thiazide 
diuretics also gives strong additional antihypertensive effect 
and is an evidence-based choice on the basis of an outcome 
study data (VALUE). On the other hand, the combination 
of a beta-blocker with a thiazide diuretic should be avoided if 
possible, particularly in subjects at increased risk of diabetes 
development.
In the 2007 guidelines of the American Heart Associa-
tion (AHA) - American Diabetes Association (ADA) for the 
management of hypertension in diabetic patients and the 2007 
guidelines of the US National Kidney Foundation KDOQI 
Clinical Practice Guidelines for the management of diabetic 
hypertensives with renal damage, it is recommended that 
antihypertensive drug treatment should be initiated with 
ACEIs or ARBs with the addition of a diuretic as a second 
drug in most cases.
The first fixed-dose combination of an ARB with a CCB 
has recently become available on the market and several 
similar combinations are expected to follow in the future. This 
combination also offers strong additional antihypertensive 
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effect and has a potential metabolic advantage compared to 
diuretic based combinations, particularly in subjects with pre-
diabetes or metabolic syndrome. An outcome study (ACCOM-
PLISH) providing a direct comparison of a combination of an 
ACEI with a dihydropiridine CCB versus an ACEI-diuretic 
combination in high risk hypertensives is expected to report 
its final results in 2008.
The combination of an ACEI with an ARB remains con-
troversial. This combination provides substantial additional 
antihypertensive effect, but lower than that obtained when 
each of these drugs is combined with a thiazide diuretic or a 
CCB. The long-term cardiovascular effects of this combina-
tion are still under investigation. There is evidence that this 
combination provides significant additional antiproteinuric 
effect in patients with diabetic or non-diabetic nephropathy 
and proteinuria. Furthermore, outcome studies in heart 
failure showed additional cardiovascular protection with 
this combination compared with ACEIs alone. On the other 
hand, one large outcome study in subjects post-myocardial 
infarction with heart failure showed no additional benefit 
with the ACEI-ARB combination compared to each of the 
monotherapies. The use of this combination in patients with 
heart failure requires close monitoring of blood pressure, 
serum creatinine and potassium. A large outcome study 
(ONTARGET) comparing an ACEI (ramipril) (n= 8576) 
with an ARB (telmisartan) (n=8542) and their combination 
(n=8502) in the prevention of cardiovascular events in high 
risk patients was just published. It reported that the ARB was 
equivalent to the ACEI in patients with vascular disease or 
high risk diabetes and was associated with less angioedema. 
The combination of the two drugs was associated with more 
adverse events without an increase in benefit. 
In a substantial proportion of hypertensive patients, the 
recommended blood pressure goal is not achieved despite 
the use of two drugs. The most popular triple combination 
is a renin-angiotensin blocker with a thiazide diuretic and a 
CCB. In most cases triple antihypertensive drug therapy can 
be administered altogether in the morning, provided that long 
acting drugs with full 24-hour coverage are used. If needed, 
more drugs might be added, with preference in first line drugs, 
often at higher than usual dosing and some of the drugs might 
be administered before night-time sleep. Patients with resist-
ant hypertension should be referred to a special hypertension 
clinic for further investigation and management.
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